candesartan + indapamide

**candesartan + indapamide** is a fixed-dose combination drug used for the treatment of essential hypertension in adults whose blood pressure is controlled by candesartan (an angiotensin II receptor blocker) and indapamide (a thiazide-like diuretic) administered separately at equivalent doses[2][1]. Candesartan lowers blood pressure by blocking angiotensin II type 1 receptors, leading to vasodilation and reduced aldosterone secretion, while indapamide inhibits the Na+/Cl- cotransporter at the distal convoluted tubule in the nephron, increasing the excretion of sodium and water and thus reducing plasma volume and cardiac output[6][2][1]. This combination is designed to improve patient compliance by replacing older combinations (such as those with hydrochlorothiazide) and is recommended in clinical guidelines for antihypertensive therapy. Combination therapy using these agents is associated with improved blood pressure control and better clinical outcomes, especially in patients inadequately controlled on monotherapy[1][2].

Brand names

CandeIndaCandeInda APONTIS

Other names

candesartan and indapamidecandesartan plus indapamide